NICE rejected crizanlizumab on cost grounds even with a discount, setting a hard WAC ceiling for the next UK sickle cell entrant.

Hydroxycarbamide remains NHS standard of care but is markedly underused, with only 25-30% of eligible UK SCD patients receiving it, leaving an estimated 4,000-6,000 of the UK's 13,000-15,000 SCD patients inadequately controlled and without any approved novel agent. That white space is real: crizanlizumab, reviewed by NICE in 2021 under TA743, was not recommended for routine NHS commissioning on cost-effectiveness grounds, and its marketing authorisation was later withdrawn in 2023 following the EMA's decision. Voxelotor was withdrawn by the FDA in September 2024, leaving the roughly 500-700 UK patients who had accessed crizanlizumab back on hydroxycarbamide or exchange transfusion alone. Casgevy, MHRA-approved in November 2023, is NICE-recommended under a managed access agreement, TA1044, while NHS gene therapy commissioning remains 2-3 years away.

The critical precedent is crizanlizumab's own NICE rejection: at a UK list price of roughly £88,000 a year, even with a confidential discount, the modelled cost per QALY landed at £733,000-1,100,000, far outside any NICE threshold, and the drug was turned down despite clear clinical need. NHS Hospital Episode Statistics put annual crisis-related hospitalisation at 10,000-15,000 admissions, costing £3,000-5,000 each; a novel agent reducing crisis frequency by 40-45% generates an estimated £2,000-5,625 per patient a year in NHS hospitalisation savings. The pre-launch pricing target follows directly: a WAC of £15,000-25,000 a year, roughly a third of crizanlizumab's list price, with the hospitalisation-offset argument built into the economic case from the outset.

Price, not clinical rationale, is the only thing still genuinely open here.

Five questions this report answers:

Q1 - What does NICE's rejection of crizanlizumab on cost grounds mean for a new agent's pricing?

Q2 - How large is the UK post-withdrawal SCD white space, and how is it identified?

Q3 - What hospitalisation cost-offset model and KOL sequence make a UK SCD submission viable?

Q4 - What must a pre-launch sickle cell disease asset prove to succeed in the UK market?

Q5 - What deliverables and verification standard does every AXLRx UK SCD assessment include?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SickleCellDisease #UK #NICE #NHS #LaunchReadiness #RareDisease

Live report page:  https://axlrx.ai/sickle-cell-disease/uk/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-     hello@axlrx.ai

Web-     https://axlrx.ai/